This study investigated the suitability of Avaxim ® and Vaqta ® as Hepatitis A booster vaccines 6 months after priming with the combined Hepatitis A/typhoid vaccine, Viatim ® . One hundred and twenty adults were randomly assigned to one of the three groups. Group A (reference group) received Avaxim ® then Avaxim ® (n=40), Group B received Viatim ® then Avaxim ® (n=41) and Group C received Viatim ® then Vaqta ® (n=39). One month after booster vaccination, anti-Hepatitis A virus (anti-HAV) antibodies geometric mean concentrations (GMC) of subjects primed with Viatim ® were non-inferior to the group primed and boosted with the monovalent Hepatitis A vaccine Avaxim ® . Anti-Salmonella typhi capsular polysaccharide virulence antigen (anti-Vi) GMCs in groups primed with Viatim ® were protective and all vaccines were well-tolerated. Therefore, Viatim ® may be used as a primary HAV vaccine with either Avaxim ® or Vaqta ® as Hepatitis A boosters and it will provide the same protection as two doses of Avaxim ® .